by Keishi Foecke | Feb 18, 2026 | Blog Post
Life sciences mergers and acquisitions (M&A) activity gained momentum in late 2025, and that acceleration is expected to continue in 2026. This positive trend is vitally important for the many treatments and cures that depend on these partnerships to reach...
by Keishi Foecke | Dec 19, 2025 | Blog Post
This year, life sciences mergers and acquisitions (M&A) played a crucial role in driving innovation and supporting America’s global leadership in the life sciences. As the leading advocacy coalition on life sciences M&A, PULSE educated stakeholders and...
by Keishi Foecke | Dec 10, 2025 | Blog Post
Following a challenging funding and policy environment, new data shows an uptick in biopharmaceutical mergers and acquisitions (M&A). This is an encouraging sign of a healthy biopharmaceutical innovation ecosystem. As experts observe continued funding pressures on...
by Keishi Foecke | Nov 20, 2025 | Innovations Advanced by M&A
This blog is another installment in a series, Innovations Advanced by M&A, that underscores the unique role of mergers and acquisitions in promoting a competitive and innovative life sciences ecosystem for patients. You can find previous blogs in this series here....
by Keishi Foecke | Nov 6, 2025 | Blog Post
Despite decades of biomedical breakthroughs, 95% of the 7,000 identified rare diseases still lack an approved treatment or cure. While these diseases may be individually rare, they collectively impact 1 in 10 Americans. To address these unmet medical needs requires...
by Keishi Foecke | Oct 22, 2025 | Blog Post
Recent commentary from senior Federal Trade Commission (FTC) and Department of Justice (DOJ) officials signaled a continued commitment to activist antitrust enforcement – compounding the uncertainty for thousands of small and early-state life science companies that...
by Keishi Foecke | Oct 9, 2025 | Blog Post
In a recent study published in Concurrences Law & Economics, Cornerstone Research experts found a significant association between biopharmaceutical mergers and acquisitions (M&A) and the likelihood of new and novel therapies coming to market. After analyzing...
by Keishi Foecke | Sep 30, 2025 | PULSE Partner
In this guest blog, Kristin Jones, CEO of PULSE Partner Indiana Life Sciences Association, discusses how pro-competitive mergers and acquisitions (M&A) have played a crucial role in supporting collaborations between universities, academic researchers and life...
by Keishi Foecke | Sep 4, 2025 | Blog Post
Following a recent Trump Administration executive order, the Federal Trade Commission (FTC) and Department of Justice (DOJ) both released statements signaling a shift to a more balanced approach to mergers and acquisitions (M&A)...
by Keishi Foecke | Aug 28, 2025 | Blog Post
Investment in early-stage life sciences companies is critical to sustain America’s global leadership in discovering and developing new medical breakthroughs for patients, according to a recent General Catalyst blog, “The Future of Life Sciences Investment.”...
